Connect with UsInvestorsCareersMediaScienceContact Us
HomeOur ProductsFocus AreasInflammation & Immunology | Development and Treatment Inflammation & Immunology | Development and Treatment 

Pfizer’s research covers multiple facets of immunology, and we continue to develop and improve the treatment and therapy of inflammation-related diseases for patients in Hong Kong. Our goal is to transform chronic inflammatory diseases, many of which are poorly managed by existing treatments that provide only symptom relief. We seek to address the root cause of this inflammation at a molecular level.  

Inflammation is a critical response to potential danger signals and damage in organs in our body. But with autoimmune diseases such as rheumatoid arthritis, lupus, ulcerative colitis, Crohn's disease, and many others, our own immune system turns against our organs. These painful and debilitating conditions take an immense toll on people's quality of life and many of these diseases are poorly managed by existing treatments that provide only symptomatic relief.  

For decades, doctors relied on steroids to suppress immune response. Though an important option, steroids come with many potentially harmful side effects. Fortunately, science has continued to advance, and today we have the opportunity to transform the management of inflammatory diseases with new classes of therapies that target other key proteins and pathways in the body.  

As science evolves beyond broad immunosuppression and into more selective agents, patients living with autoimmune and inflammatory disease have new hope. As a global leader in developing medicine, treatment, and therapy for patients suffering from chronic inflammation and autoimmune diseases, we continue to research and expand our disease biology understanding and identify biomarkers that impact these areas:

Immunology Research and Developments in Hong Kong 

Recent immunology research in Hong Kong has found that inflammatory bowel disease has been growing in our city at an alarming rate¹. Similar findings should be seen as an alert to Hong Kong’s healthcare system, as complicated autoimmune diseases like Crohn’s disease are yet to have a definitive cure. 

Symptoms of the autoimmune disease, such as abdominal pain and diarrhoea, are often overlooked by patients in Hong Kong², causing treatment to be delayed. Timely and accurate diagnosis of an inflammation can significantly enhance the efficiency of the subsequent treatment and therapy and prevent life-threatening complications. Aside from medical research, raising the public’s awareness on these health issues is of utmost importance.   

Existing inflammation treatments and therapies can help reduce symptoms and limit complications. Pfizer’s immunology research continues to make important contributions to developing medicines and therapies for complicated, inflammatory disorders to provide better treatments for patients in Hong Kong. 

References:
  1. Hong Kong ranks third for new cases of bowel disease, behind South Korea and Guangzhou, say CUHK researchers. Available at: https://www.scmp.com/news/hong-kong/health-environment/article/2115756/hong-kong-ranks-third-new-cases-bowel-disease. Last accessed May 2022.

  2. Gastrointestinal Manifestations in Systemic Autoimmune Diseases. Maedica. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150032/. Last accessed May 2022. 

PP-UNP-HKG-0063
Careers News Useful LinksHealthcare ProfessionalUseful LinksPrivacy PolicyTerms of UseConnect with Us Privacy statement Terms of Use Distributors Grant Seekers Media Copyright © 2022 pfizer inc. The product information provided in this site is intended only for health professionals who reside in hong kong, and the products discussed herein may have different product labeling in different countries/regions. Pfizer corporation hong kong limited is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.